BioAscent’s latest investment in a state-of-the-art Seahorse XF Pro Analyser Platform has strengthened the company’s mitochondrial biology capabilities. This cutting-edge technology is set to revolutionise our approach to addressing bioenergetic questions and enhancing our understanding of cellular metabolic functions.

The Seahorse XF Pro Analyser Platform enables simultaneous monitoring of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), providing a comprehensive view of energy production shifts from oxidative phosphorylation (OxPhos) to glycolysis. This advanced system allows us to investigate mitochondrial function in response to pharmacologic inhibitors, effectors, or genetic interventions in a robust and high-throughput fashion.

This investment allows us to explore mitochondrial function in greater detail. By using uncouplers like FCCP or BAM15, we can increase cellular energy demand, uncovering metabolic changes that might otherwise go unnoticed. The platform also enables real-time measurement of metabolic shifts in response to biologically relevant stimuli—for example, activating T cells with anti-CD3 and anti-CD28 antibodies or stimulating brown adipocytes with norepinephrine. These capabilities provide deeper insights into how cells adjust their energy production in different conditions.

Optimising Seahorse XF assay conditions is key to studying specific metabolic pathways and signaling mechanisms. By carefully selecting energy sources such as glucose, glutamine, pyruvate, or galactose, we can design experiments that provide deeper insights into cellular metabolism—delivering precise, data-driven results to support and accelerate our customers’ drug discovery projects.

For more information on mitochondrial biology services from the team at BioAscent, click here.